Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Caribou Biosciences (CRBU) Income towards Parent Company (2020 - 2025)

Caribou Biosciences has reported Income towards Parent Company over the past 6 years, most recently at -$28.5 million for Q4 2025.

  • Quarterly Income towards Parent Company rose 26.81% to -$28.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$148.3 million through Dec 2025, up 10.97% year-over-year, with the annual reading at -$148.1 million for FY2025, 0.66% up from the prior year.
  • Income towards Parent Company was -$28.5 million for Q4 2025 at Caribou Biosciences, up from -$29.4 million in the prior quarter.
  • Over five years, Income towards Parent Company peaked at -$13.2 million in Q1 2021 and troughed at -$47.6 million in Q2 2025.
  • The 5-year median for Income towards Parent Company is -$30.0 million (2022), against an average of -$30.2 million.
  • Year-over-year, Income towards Parent Company plummeted 664.48% in 2021 and then surged 44.86% in 2023.
  • A 5-year view of Income towards Parent Company shows it stood at -$18.5 million in 2021, then tumbled by 65.47% to -$30.6 million in 2022, then fell by 22.45% to -$37.4 million in 2023, then dropped by 3.83% to -$38.9 million in 2024, then increased by 26.81% to -$28.5 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Income towards Parent Company are -$28.5 million (Q4 2025), -$29.4 million (Q3 2025), and -$47.6 million (Q2 2025).